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This is a pharma industry generated international study. It involves a single treatment of botulinum toxin type A (BoNT-A) and patients are then followed up with post-injection therapy. The study recognises the fact the BoNT-A is an adjunct to physical treatment for poststroke spasticity and this highlights the difficulty of carrying out such a study across the world. The differences in financing and organising health care for stroke survivors, as well as the different relationships between physician and patients make reporting difficult. However, health systems need to know whether there is a long term advantage to treating patients with BoNT-A for a long term health condition, such as stroke and the outcome of a single treatment may not be as helpful as an outcome at, say, one year. For instance, there was no control into the type and amount of post-injection physical treatment subjects received. Was this the defined at least for patients within each centre? In addition, controlling the review date, i.e. the primary end-point would, in my view, important.
Are the amount and type of physical interventions give in the participating centres controlled in any way? If not, the results of the outcomes will be "skewed" considerably.
The paper imparts a lot of useful information on the ULIS-II study, but may need to focus down on Goal Attainment Scaling (GAS) to make the paper clearer.
I cannot comment specifically on the results and statistical analysis, as there are no data on these in the paper, but those planned.
The approach to GAS is very thorough and perhaps, too much so to suggest that it will be used in a busy clinical setting. For the purpose of the study, this is fine, but a more simple design may be better in clinical practice.
The benefit of this study and others is that it will lead to more precise goal setting in both spasticity management, but also in specialist rehabilitation, but this quite a specialised area of clinical medicine and would, perhaps, better suit a specific specialist journal.
The study is also limited by the lack of a control group to show that either rehabilitation is effective in patients meeting their goals of, more specifically, that BoNT-A works.
RESULTS & CONCLUSIONS
The outcomes and results of the BoNT-A intervention are not reported -this paper simply reports on the ULIS-II study rationale and protocol. I think this paper would be better directed at a more specialist journal, rather than the more general readership of the BMJ for the reasons given above.
I also think it is difficult to convey the variation of injection practices of clinicians across the world to be of real interest to a general readership and would thus omit some of the recruitment detail and Table 1 from the paper.
REPORTING & ETHICS
The reporting and ethical issues are fine.
GENERAL COMMENTS
I must declare a potential conflict of interest in that I am the Chief Investigator of another study (BEST Trial), which has been submitted to Stroke for publication. The methodology of the BEST was also published prior to in the same way as this study has been written up. The definitive BEST paper will appear in early 2013.
Page 5, line 21-22. "...(BoNT-A) is a safe and effective focal intervention......" -The ABPI has not approved of the word "safe" in respect of BoNT-A and the phrase "well-tolerated" is more acceptable.
In conclusion, this is a good paper on the protocol and development of GAS, which does not contain the results of the study of the intervention itself and which would, in my view, be more appropriately considered by a specialist rehabilitation medicine/stroke or neurology journal.
Correction required to Reference 7 -date is 2009, not 2008.
The paper did not exactly fit into the categories on the scoring grid above and I have thus placed negative mark against these. 468 patients with post-stroke upper limb spasticity in whom the decision had already been made to inject BoNT-A were included. In that trail physicians were free to choose the muscles injected, BoNT-A preparation, doses, injection technique, timing of follow-up and the treatment goals. Goal attainment of that treatment goals measured with a goal attainment scaling (GAS) was the primary outcome measure. Secondary outcome measurements include spasticity ratings and global benefits from the single shot treatment. All subjects who had a BoNT-A injection and a subsequent assessment of GAS were included in the analysis. The results will be published separately.
REVIEWER
As well the rationale and steps to ensure validity of goal attainment scaling (GAS) used in the ULIS II study are presented and discussed in the paper and an electronic case report form was established. All investigators were trained in using of the GAS beforehand and while the beginning of the study goal statements of all centres were validated by three specialists in the field.
This study will report only open label data, which is a disadvantage, but ULIS II included a big cohort and will represent so called "real world data" (representing what physicians are doing in their every day practise) documented prospectively which allows to discuss several interesting aspects of post-stroke spasticity upper limb treatment like muscle selection, dosing, and so on. Another interesting and important aspect of the article is the presentation of the rational and the discussion of the steps to ensure validity of the GAS in ULIS II.
I have no further comments. This article is qualified for publication in BMJ open. I am looking forward to see the results of ULIS II soon.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 comment: This is a pharma industry generated international study. It involves a single treatment of botulinum toxin type A (BoNT-A) and patients are then followed up with post-injection therapy. The study recognises the fact the BoNT-A is an adjunct to physical treatment for post-stroke spasticity and this highlights the difficulty of carrying out such a study across the world. The differences in financing and organising health care for stroke survivors, as well as the different relationships between physician and patients make reporting difficult. However, health systems need to know whether there is a long term advantage to treating patients with BoNT-A for a long term health condition, such as stroke and the outcome of a single treatment may not be as helpful as an outcome at, say, one year. For instance, there was no control into the type and amount of postinjection physical treatment subjects received. Was this the defined at least for patients within each centre? In addition, controlling the review date, i.e. the primary end-point would, in my view, important.
Response: If this were an experimental design we would agree with the reviewer. However, other RCTs have already demonstrated the effectiveness of BoNT-A using Goal attainment scaling in the context of a controlled study design (see refs 24 and 25). As explained on page 7 of the manuscript, it is recognised that there is currently considerable variation in routine practice -both with respect to approaches to injection and the provision of concomitant therapies. This variation appears to have more to do with clinician bias and local availability of services than with patient presentation. We agree that this may influence the outcome, and in order to understand how BoNT-A is used and what works in real-life clinical practice we need to be able to describe this variation. Horn and Gassaway 2007 argue that this type of "practice-based evidence" is as important in its own right as the information that derives from controlled clinical trials for building the evidence base for clinical practice.
The ULIS programme therefore consists of a series of international, non-interventional observational studies to describe current clinical practice in the application of BoNT-A in the management of upper limb spasticity. The purpose of this programme is to describe what actually happens in normal day-today practice -including the levels of provision of Physio / O/T and other therapies. We have added slightly to the overview section to try to bring this out more clearly.
We agree with the reviewer that it is important to capture longer term outcomes and the results of repeated injection where this is used. This will be captured in ULIS-III which is currently in the planning and pre-investigation phase. Again we have added a sentence to clarify this point Reviewer 1 comment: The paper imparts a lot of useful information on the ULIS-II study, but may need to focus down on Goal Attainment Scaling (GAS) to make the paper clearer.
Response: The methods used for goal attainment scaling (GAS) are already published in considerable detail in our practical guide in Clinical Rehabilitation (reference 28). However, for further clarity in this article, we have expanded further the description of the GAS-light method, and have provided an additional figure (figure 3) which explains how the 5-point numerical GAS scale is derived from the 6-point verbal scale. We have also provided a direct web link to our website at the Cicely Saunders Institute, where readers may find further information and may download freely copies of our own full practical guide, as well as copied of the GAS T score calculator, should they wish to do so.
Reviewer 1 comment: I cannot comment specifically on the results and statistical analysis, as there are no data on these in the paper, but those planned.
Response: This is a very important point and we entirely agree with the requirement to make GAS as simple as possible to apply in clinical practice. A major criticism of the original GAS method as described by Kiresuk and Sherman is that it is too cumbersome for routine clinical use.
In the course of the ULIS programme we have progressively refined and simplified the approach to using GAS, and also worked closely with all the participating centres to make it understandable and usable in clinical practice around the world. The "GAS-light" method used in ULIS-II was specifically designed to be practical for use in the clinical setting, and as a result of this study, we have subsequently refined the method further to produce an even simpler and more structured approach (the GASeous tool) which will be used in ULIS-III. However, this had not yet been developed in the planning stage of ULIS-II that is described here.
Reviewer 1 comment: The benefit of this study and others is that it will lead to more precise goal setting in both spasticity management, but also in specialist rehabilitation, but this quite a specialised area of clinical medicine and would, perhaps, better suit a specific specialist journal.
Response: We appreciate that treatment of ULS is a specialist area. However, GAS is a generic outcome measure, which has been widely applied in many areas of clinical practice. We believe that the novel approach taken here to enhancing the validity of GAS has addressed some of the general criticisms of GAS methodology and has potential application in many other areas of medicine. Therefore we believe that this study is of methodological interest to a much wider audience than just those involved with the management of spasticity. Hence we believe that publication in a more general journal is appropriate.
Reviewer 1 comment: The study is also limited by the lack of a control group to show that either rehabilitation is effective in patients meeting their goals of, more specifically, that BoNT-A works.
Response: Addressed above.
Reviewer 1 comment: The outcomes and results of the BoNT-A intervention are not reported -this paper simply reports on the ULIS-II study rationale and protocol. I think this paper would be better directed at a more specialist journal, rather than the more general readership of the BMJ for the reasons given above.
